ELVN:NSD-Enliven Therapeutics Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 25.8

Change

-1.37 (-5.04)%

Market Cap

N/A

Volume

0.28M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing ELVN

CNCR Loncar Cancer Immunothera.. 1.70 % 0.79 %

-0.29 (-1.93%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 86.42% 89% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.42% 89% A- 93% A
Trailing 12 Months  
Capital Gain 135.62% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.62% 88% B+ 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 12.25% 59% D- 65% D
Dividend Return 12.25% 59% D- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.73% 79% B- 56% F
Risk Adjusted Return 36.31% 88% B+ 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector